NeuroHealing Announces Orphan Drug Designation in Europe for NH001 for the Treatment of Patients Following a Moderate or Severe Traumatic Brain Injury

Provides a 10-Year Regulatory Exclusivity for the European Community Newton, Massachusetts – May 23, 2011. NeuroHealing Pharmaceuticals today announced that the European Commission has granted Orphan Drug Designation EU/3/11/862 for NH001 for the treatment of patients following a moderate or severe traumatic brain injury (TBI). The designation follows a positive opinion from the Committee for…